Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist.

Autor: Hudzik TJ; AstraZeneca R & D, Wilmington, Massachusetts, USA. thomas.hudzik@astrazeneca.com, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M, Ryan C, Ross S, Stenfors C

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2003 Mar; Vol. 304 (3), pp. 1072-84.

AR-A000002, a high affinity 5-HT 1B receptor antagonist: Evaluation of its anxiolytic potential

Autor: Ryan, C., Hudzik, T.J., Yanek, M., Porrey, T., Evenden, J., Paronis, C., Mastrangelo, M., Ross, S.B., Stenfors, C.

Publikováno v: In European Neuropsychopharmacology 2001 11 Supplement 3:S307-S307

Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain.

Autor: Yang KC; Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden. kcyang2@vghtpe.gov.tw., Stepanov V; Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden., Amini N; Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden., Martinsson S; Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden., Takano A; Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden., Bundgaard C; Molecular Discovery and Innovation, H. Lundbeck A/S, Valby, Denmark., Bang-Andersen B; Molecular Discovery and Innovation, H. Lundbeck A/S, Valby, Denmark., Sanchez C; Lundbeck Research USA, Paramus, NJ, 07652, USA., Halldin C; Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden., Farde L; Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.; Personalized Health Care and Biomarkers, AstraZeneca PET Science Center at Karolinska Institutet, Stockholm, Sweden., Finnema SJ; Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.; Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA.

Publikováno v: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2019 Sep; Vol. 44 (10), pp. 1706-1713. Date of Electronic Publication: 2019 Jun 19.

Dose–Response Effect of Antibodies to S100 Protein and Cannabinoid Receptor Type I in Released-Active Form in the Light–Dark Test in Mice.

Autor: Kardash, Elena V.¹ (AUTHOR), Ertuzun, Irina A.² (AUTHOR) nauka@materiamedica.ru, Khakimova, Gul’nara R.² (AUTHOR), Kolyadin, Andrey N.² (AUTHOR), Tarasov, Sergey A.¹ (AUTHOR), Wagner, Stéphanie³ (AUTHOR), Andriambeloson, Emile³ (AUTHOR), Ivashkin, Vladimir T.⁴ (AUTHOR), Epstein, Oleg I.¹ (AUTHOR)

Publikováno v: Dose-Response. Apr-Jun2018, Vol. 16 Issue 2, p1-7. 7p. 3 Charts, 1 Graph.

The guinea pig forced swim test as a new behavioral despair model to characterize potential antidepressants.

Autor: Wicke, Karsten M.¹ karsten.wicke@abbott.com, Rex, Andre², Jongen-Relo, Ana¹, Groth, Ilona¹, Gross, Gerhard¹

Publikováno v: Psychopharmacology. Nov2007, Vol. 195 Issue 1, p95-102. 8p. 1 Diagram, 9 Graphs.